Transcept Pharmaceuticals Inc (TSPT) is a publicly traded company in the Unknown sector. Across all available filings, 26 corporate insiders have executed 131 transactions totaling $15.0M, demonstrating a bullish sentiment with $1.9M in net insider flow. The most recent transaction on Oct 30, 2014 involved a transaction of 10,613 shares valued at $229.1K.
No significant insider buying has been recorded for TSPT in the recent period.
No significant insider selling has been recorded for TSPT in the recent period.
Based on recent SEC filings, insider sentiment for TSPT is bullish with an Insider Alignment Score of 56/100 and a net flow of $1.9M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Transcept Pharmaceuticals Inc (TSPT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 26 insiders are actively trading TSPT stock, having executed 131 transactions in the past 90 days. The most active insider is Christopher B. Ehrlich (Executive), who has made 3 transactions totaling $5.0M.
Get notified when executives and directors at TSPT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 30, 2014 | A. Oclassen Glenn | Executive | Award | 10,613 | $21.59 | $229.1K | |
| Oct 30, 2014 | A. Kollins John | Executive | Award | 4,161 | $21.59 | $89.8K | |
| Oct 30, 2014 | D. Patterson Leone | Executive | Award | 4,161 | $21.59 | $89.8K | |
| Oct 30, 2014 | N. Singh Nikhilesh | Executive | Award | 11,758 | $21.59 | $253.9K | |
| Oct 30, 2014 | John Dietz Thomas | Executive | Award | 5,430 | $N/A | $0 | |
| Dec 13, 2013 | Management, Llc Roumell Asset | Executive | Sale | 1,470 | $3.54 | $5.2K | |
| Dec 11, 2013 | Management, Llc Roumell Asset | Executive | Sale | 520 | $3.53 | $1.8K | |
| Dec 11, 2013 | Management, Llc Roumell Asset | Executive | Sale | 500 | $3.57 | $1.8K | |
| Dec 10, 2013 | Management, Llc Roumell Asset | Executive | Sale | 9,470 | $3.55 | $33.6K | |
| Dec 9, 2013 | Management, Llc Roumell Asset | Executive | Other | 2,030 | $N/A | $0 | |
| Dec 6, 2013 | Management, Llc Roumell Asset | Executive | Sale | 8,710 | $3.54 | $30.8K | |
| Dec 4, 2013 | Management, Llc Roumell Asset | Executive | Sale | 5,450 | $3.50 | $19.1K | |
| Dec 3, 2013 | Management, Llc Roumell Asset | Executive | Sale | 1,670 | $3.50 | $5.8K | |
| Nov 26, 2013 | Management, Llc Roumell Asset | Executive | Other | 1,800 | $N/A | $0 | |
| Nov 26, 2013 | Management, Llc Roumell Asset | Executive | Other | 1,840 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 10 | $8.4M | 50.2% |
Sale(S) | 55 | $6.5M | 38.9% |
Exercise(M) | 19 | $1.0M | 6.1% |
Award(A) | 22 | $798.7K | 4.8% |
Other(J) | 24 | $0 | 0.0% |
Gift(G) | 1 | $0 | 0.0% |
Insider activity at Transcept Pharmaceuticals Inc shows mixed signals across all time. While $8.4M in purchases indicates some executive confidence,$6.5M in sales balances the picture, resulting in a modest net flow of $1.9M.26 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Christopher B. Ehrlich, has transacted $5.0M during this period.